These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32374879)

  • 21. Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.
    Yee A; Oleskie AN; Dosey AM; Kretz CA; Gildersleeve RD; Dutta S; Su M; Ginsburg D; Skiniotis G
    Blood; 2015 Aug; 126(8):939-42. PubMed ID: 26065653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.
    Stennicke HR; Kjalke M; Karpf DM; Balling KW; Johansen PB; Elm T; Øvlisen K; Möller F; Holmberg HL; Gudme CN; Persson E; Hilden I; Pelzer H; Rahbek-Nielsen H; Jespersgaard C; Bogsnes A; Pedersen AA; Kristensen AK; Peschke B; Kappers W; Rode F; Thim L; Tranholm M; Ezban M; Olsen EH; Bjørn SE
    Blood; 2013 Mar; 121(11):2108-16. PubMed ID: 23335368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
    Di Brino E; Yan S; Tomic R; Panebianco M; Dlotko E; Stern L; Basile M; Rumi F; Cicchetti A; Marino R
    J Med Econ; 2023; 26(1):554-564. PubMed ID: 37039544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.
    Glantschnig H; Bauer A; Benamara K; Dockal M; Ehrlich V; Gritsch H; Höbarth G; Horling FM; Kopic A; Leidenmühler P; Reipert BM; Rottensteiner H; Ruthsatz T; Schrenk G; Schuster M; Turecek PL; Weber A; Wolfsegger M; Scheiflinger F; Höllriegl W
    J Pharmacol Exp Ther; 2019 Oct; 371(1):95-105. PubMed ID: 31366602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bringing new therapy options to the hemophilia community.
    Bensen-Kennedy D
    Thromb Res; 2013 Mar; 131 Suppl 2():S15-8. PubMed ID: 23537722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
    Vollack-Hesse N; Oleshko O; Werwitzke S; Solecka-Witulska B; Kannicht C; Tiede A
    Blood; 2021 Feb; 137(8):1072-1081. PubMed ID: 32877516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated plasma factor VIII enhances venous thrombus formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor.
    Sugita C; Yamashita A; Matsuura Y; Iwakiri T; Okuyama N; Matsuda S; Matsumoto T; Inoue O; Harada A; Kitazawa T; Hattori K; Shima M; Asada Y
    Thromb Haemost; 2013 Jul; 110(1):62-75. PubMed ID: 23636277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic evaluation of efanesoctocog alfa: breakthrough factor VIII therapy for hemophilia A.
    Yada K; Nogami K
    Expert Opin Drug Metab Toxicol; 2024 Oct; ():1-10. PubMed ID: 39323385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.
    Chiu PL; Bou-Assaf GM; Chhabra ES; Chambers MG; Peters RT; Kulman JD; Walz T
    Blood; 2015 Aug; 126(8):935-8. PubMed ID: 26065652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP.
    Oldenburg J; Pipe SW; Mancuso ME; Klamroth R; Hassoun A; Olivieri M; Goldmann G; Kenet G; Miesbach W; Schmiedl J; Hegemann I
    Curr Med Res Opin; 2023 Feb; 39(2):219-225. PubMed ID: 36170120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging drugs for the treatment of hemophilia A and B.
    Morfini M; Zanon E
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux.
    Szlam F; Sreeram G; Solomon C; Levy JH; Molinaro RJ; Tanaka KA
    Thromb Res; 2011 Feb; 127(2):135-40. PubMed ID: 21144556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
    Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
    Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
    Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
    Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
    Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
    Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiological Roles of the von Willebrand Factor-Factor VIII Interaction.
    Kiouptsi K; Reinhardt C
    Subcell Biochem; 2020; 94():437-464. PubMed ID: 32189311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease.
    Turecek PL; Gritsch H; Richter G; Auer W; Pichler L; Schwarz HP
    Thromb Haemost; 1997 Mar; 77(3):591-9. PubMed ID: 9066015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.